SBX BioSciences, Inc is a private corporation which was established in 2020 in Vancouver as a Canadian subsidiary of SBX Corporation to provide professional service and end-to-end research solution building towards predictive biology through integrating AI and computational systems biology, and platform-empowered research by partnering with the group entities.
The vision of the group is to Create an Engine of Scientific Discovery that would improve the state of the world and provide a meaningful impact on the lives of billions of people. The voyage began with Systems Biology Institute (SBI), a private non-profit research institution founded in 2000 by Dr. Hiroaki Kitano, with the aim of promoting systems biology research and its application to medicine and global sustainability. SBI focuses on the rapid translation of basic research to practical outcomes for both business and clinical applications.
Led by a pioneer in systems biology, and with a number of experiences in building AI and its platform in close partnership with global leaders in pharmaceutical, cosmetic and manufacturing industries, we will focus on building solutions which address core problems in biology and healthcare which impact the way we do science.
President and CEO
Ayako Yachie is CEO of SBX Biosciences, Inc. based in Vancouver, newly established as a subsidiary of SBX Corporation in Japan. She also serves as a director of research in SBX Corporation and a senior scientist in the Systems Biology Institute (SBI) in Tokyo, which are represented by Dr. Hiroaki Kitano.
She received her Ph.D. at the Bioinformatics/Systems Biology Program of Keio University in Japan, and was trained at the medical school of Keio University and the University of Toronto focusing on computational modeling in metabolism and stem cell bioengineering.
After she joined SBI and the group company SBX, she has led a number of projects on research and consultancy for drug discovery, translational research pipelines and industrial biotechnology processes with and for a number of companies including Fortune 500 companies in pharmaceutical and healthcare and academic institutions.
Our key strength underpinning the project’s success is to develop a scientific solution and a platform to predict and understand the living systems through the integration of Systems Biology pipelines and Artificial Intelligence, together with the system development and scaling of the projects using the core platform technologies.